Copyright
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Jan 26, 2026; 18(1): 111954
Published online Jan 26, 2026. doi: 10.4330/wjc.v18.i1.111954
Published online Jan 26, 2026. doi: 10.4330/wjc.v18.i1.111954
Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: A state-of-the-art review
Ajit Singh Brar, Department of Internal Medicine, Michigan State University at Hurley Medical Center, Flint, MI 48503, United States
Tejasvini Khanna, Department of Medicine, Maulana Azad Medical College, New Delhi 110002, India
Aalam Sohal, Department of Gastroenterology and Hepatology, Creighton University School of Medicine, Phoenix, AZ 85012, United States
Juniali Hatwal, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India
Vishal Sharma, Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
Carol Singh, Department of Internal Medicine, Dayanand Medical College and Hospital, Ludhiana 141001, Punjab, India
Akash Batta, Bishav Mohan, Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana 141001, Punjab, India
Praveen Chandra, Department of Cardiology, Medanta-The Medicity, Gurgaon 122001, Haryāna, India
Author contributions: Brar AS and Batta A designed the review; Brar AS, Khanna T, Sohal A and Hatwal J performed the literature review and data collection; Sharma V, Mohan B, Chandra P and Singh C supervised the manuscript and provided key feedback and suggestions; Brar AS and Batta A analyzed the data, wrote the manuscript and subsequently revised it; all authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Akash Batta, MD, Associate Professor, Department of Cardiology, Dayanand Medical College and Hospital, Tagore Nagar, Civil Lines, Ludhiana 141001, Punjab, India. akashbatta02@gmail.com
Received: July 14, 2025
Revised: August 4, 2025
Accepted: November 24, 2025
Published online: January 26, 2026
Processing time: 185 Days and 8.6 Hours
Revised: August 4, 2025
Accepted: November 24, 2025
Published online: January 26, 2026
Processing time: 185 Days and 8.6 Hours
Core Tip
Core Tip: The ever-changing terminology of metabolic dysfunction-associated steatotic liver disease (MASLD) to encompass metabolic dysfunction truly reflects its systemic impact beyond the liver. Cardiovascular diseases remain the leading cause of MASLD-related morbidity and mortality. Amongst the various cardiovascular diseases linked to MASLD, heart failure with preserved ejection fraction (HFpEF) is most closely related to MASLD, sharing a pathophysiologic foundation with MASLD and rooted in common metabolic risk factors. This review explores the intertwined mechanisms linking MASLD and HFpEF, highlighting their clinical convergence and therapeutic relevance.